BPH Energy BPH.AX · AUD

Its shares trade on ASX under the ticker BPH.AX. It has been listed since 6 August 2004. In the fiscal year to 30 June 2025, it reported revenue of A$836,638 and net income of A$6.8m. At that date it held total assets of A$39.2m and shareholders' equity of A$38.7m.

BPH Energy Ltd. engages in the development of biomedical research and technologies within universities and hospital institutes. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-08-06. The firm's principal activities include Molecular Discovery Systems (MD Systems), HLS5 Project, Cortical Dynamics, Diagnostic Array Systems (DAS) and Advent Energy Limited. MD Systems a class of anti-mitotic drugs, which has undergone preclinical testing of anti-cancer activity. MD Systems is working with the Western Australian Institute for Medical Research to validate HLS5 as a tumor suppressor gene. Cortical Dynamics is working with BPH Energy and Swinburne University of Technology to commercialize anesthesia monitoring system for use during surgery. DAS is working with it to commercialize BacTrak, a diagnostic tool to enable pathology laboratories and emergency departments of hospitals to provide patients with identification of disease causing bacteria from a single sputum sample. Advent Energy Limited has its project in Petroleum Exploration Permit 11.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. David BreezeChairman of the Board, Chief Executive Officer, Managing Director, Company Secretary, since 2016A$148,000
• Dr. Sunil NagarajChief Scientific Officer
• Mr. Anthony HustonNon-Executive DirectorA$40,000
• Mr. Charles MalingNon-Executive DirectorA$25,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.